268 related articles for article (PubMed ID: 27270328)
1. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.
Qiao Y; Berg AL; Wang P; Ge Y; Quan S; Zhou S; Wang H; Liu Z; Gong R
Sci Rep; 2016 Jun; 6():27589. PubMed ID: 27270328
[TBL] [Abstract][Full Text] [Related]
2. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R
Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144
[TBL] [Abstract][Full Text] [Related]
3. Leveraging melanocortin pathways to treat glomerular diseases.
Gong R
Adv Chronic Kidney Dis; 2014 Mar; 21(2):134-51. PubMed ID: 24602463
[TBL] [Abstract][Full Text] [Related]
4. Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy.
Chen B; Guan X; Gunning WT; Ge Y; Gohara AF; Dworkin LD; Gong R
J Am Soc Nephrol; 2023 Mar; 34(3):467-481. PubMed ID: 36446431
[TBL] [Abstract][Full Text] [Related]
5. Effects of melanocortin 1 receptor agonists in experimental nephropathies.
Lindskog Jonsson A; Granqvist A; Elvin J; Johansson ME; Haraldsson B; Nyström J
PLoS One; 2014; 9(1):e87816. PubMed ID: 24498203
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy.
Guan X; Chen B; Malhotra DK; Gohara AF; Dworkin LD; Gong R
Kidney Int; 2023 Feb; 103(2):331-342. PubMed ID: 36374665
[TBL] [Abstract][Full Text] [Related]
7. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
Elvin J; Buvall L; Lindskog Jonsson A; Granqvist A; Lassén E; Bergwall L; Nyström J; Haraldsson B
Am J Physiol Renal Physiol; 2016 May; 310(9):F846-56. PubMed ID: 26887829
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin 1 receptor agonists reduce proteinuria.
Lindskog A; Ebefors K; Johansson ME; Stefánsson B; Granqvist A; Arnadottir M; Berg AL; Nyström J; Haraldsson B
J Am Soc Nephrol; 2010 Aug; 21(8):1290-8. PubMed ID: 20507942
[TBL] [Abstract][Full Text] [Related]
9. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
[TBL] [Abstract][Full Text] [Related]
10. Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Egerman MA; Wong JS; Runxia T; Mosoyan G; Chauhan K; Reyes-Bahamonde J; Anandakrishnan N; Wong NJ; Bagiella E; Salem F; Meliambro K; Li H; Azeloglu EU; Coca SG; Campbell KN; Raij L
FASEB J; 2020 Dec; 34(12):16191-16204. PubMed ID: 33070369
[TBL] [Abstract][Full Text] [Related]
11. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
12. Key amino acid residue in Melanocortin-1 receptor (melanocyte α-MSH receptor) for ligand selectivity.
Yang Y; Chen M; Ventro G; Harmon CM
Mol Cell Endocrinol; 2017 Oct; 454():69-76. PubMed ID: 28579117
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease.
Sonneveld R; Ferrè S; Hoenderop JG; Dijkman HB; Berden JH; Bindels RJ; Wetzels JF; van der Vlag J; Nijenhuis T
Am J Pathol; 2013 Apr; 182(4):1196-204. PubMed ID: 23385000
[TBL] [Abstract][Full Text] [Related]
14. Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention.
Abdel-Malek ZA; Swope VB; Starner RJ; Koikov L; Cassidy P; Leachman S
Arch Biochem Biophys; 2014 Dec; 563():4-12. PubMed ID: 25017567
[TBL] [Abstract][Full Text] [Related]
15. Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases.
Szabó T; Ambrus L; Zákány N; Balla G; Bíró T
Acta Physiol Hung; 2015 Sep; 102(3):241-51. PubMed ID: 26551740
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization.
Bergwall L; Wallentin H; Elvin J; Liu P; Boi R; Sihlbom C; Hayes K; Wright D; Haraldsson B; Nyström J; Buvall L
Sci Rep; 2018 Oct; 8(1):15731. PubMed ID: 30356069
[TBL] [Abstract][Full Text] [Related]
17. NDP-MSH binding melanocortin-1 receptor ameliorates neuroinflammation and BBB disruption through CREB/Nr4a1/NF-κB pathway after intracerebral hemorrhage in mice.
Wu X; Fu S; Liu Y; Luo H; Li F; Wang Y; Gao M; Cheng Y; Xie Z
J Neuroinflammation; 2019 Oct; 16(1):192. PubMed ID: 31660977
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis.
Chen B; Alam Z; Ge Y; Dworkin L; Gong R
Front Physiol; 2022; 13():887641. PubMed ID: 35721571
[TBL] [Abstract][Full Text] [Related]
19. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms.
Si J; Ge Y; Zhuang S; Wang LJ; Chen S; Gong R
Kidney Int; 2013 Apr; 83(4):635-46. PubMed ID: 23325074
[TBL] [Abstract][Full Text] [Related]
20. A role for MC3R in modulating lung inflammation.
Getting SJ; Riffo-Vasquez Y; Pitchford S; Kaneva M; Grieco P; Page CP; Perretti M; Spina D
Pulm Pharmacol Ther; 2008 Dec; 21(6):866-73. PubMed ID: 18992358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
